A Phase 1 interventional study of ABI-4334 and Placebo in Chronic Hepatitis B, sponsored by Assembly Biosciences. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Assembly Biosciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hepatitis B, Chronic by Assembly Biosciences — none open to participants now, none under way, none of them phase 3. Hepatitis B, Chronic · Assembly Biosciences.
Among the 17 studies in Hepatitis B, Chronic by Assembly Biosciences, this one is the 14th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 1, and was the 17th registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 17 studies in Hepatitis B, Chronic by Assembly Biosciences is open now. The open studies under Hepatitis B, Chronic, anywhere →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8
First in 2016; this study’s year is marked. 1 started in 2024.
This study's enrollment of 20 is below the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 54 across the 17 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assembly Biosciences is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Hepatitis B, Chronic by Assembly Biosciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ABI-4334
Drug: Placebo
10 mg or 50 mg tablets for oral administration
10 mg or 50 mg tablets for oral administration
To assess the safety and tolerability of ABI-4334 in subjects with cHBV following 28-day multiple oral doses
Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory results
Time frame: Through end of study, up to 56 days
To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV
Noncompartmental plasma PK parameters
Time frame: Through treatment period, up to 28 days
Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334
Mean change in log10 HBV DNA between Baseline and Day 28
Time frame: Through treatment period, up to 28 days
To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV
Area Under Plasma Concentration-Time Curve (AUC) of ABI-4334 in subjects with cHBV
Time frame: Through treatment period, up to 28 days
To characterize the PK of ABI-4334 in plasma following 28-day multiple doses in subjects with cHBV
Time to Maximum Plasma Concentration (Tmax) of ABI-4334 in subjects with cHBV
Time frame: Through treatment period, up to 28 days
Elimination half-life (t1/2) of ABI-4334 in subjects with cHBV
Time frame: Through treatment period, up to 28 days
Changes in HBV pregenomic ribonucleic acid (pgRNA) and additional markers of antiviral activity in subjects with cHBV
To evaluate the changes in HBV DNA (IU/mL or Log IU/mL) in subjects with cHBV
Time frame: Through treatment period, up to 28 days
Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334
Proportion of subjects with HBV DNA \< lower limit of quantification (LLOQ) and/or limit of detection (LOD)
Time frame: Through treatment period, up to 28 days
Changes in HBV DNA in subjects with cHBV following 28-day multiple doses of ABI-4334
Mean time elapsed to subjects achieving HBV DNA \< LLOQ and/or LOD
Time frame: Through treatment period, up to 28 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Apr 2025, 10 months.
Of 74 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 82 studies reached it within 16 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.